JP2022551580A - 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置 - Google Patents

巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置 Download PDF

Info

Publication number
JP2022551580A
JP2022551580A JP2022520229A JP2022520229A JP2022551580A JP 2022551580 A JP2022551580 A JP 2022551580A JP 2022520229 A JP2022520229 A JP 2022520229A JP 2022520229 A JP2022520229 A JP 2022520229A JP 2022551580 A JP2022551580 A JP 2022551580A
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
aryl
optionally substituted
rac1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551580A5 (https=
Inventor
フランシス レイリー，ジョン
ダゴン，ヨッシ
ラグー，ハリ
ギャル，マリ－フランソワーズ イヴリーヌ コエフェ－ル
エイチ ダニエルズ，マシュー
ユ，マオリン
ダブリュー レデボー，マーク
ペ アルマンジ，ジャン－クリストフ
エイチ マンデル，ピーター
Original Assignee
ゴールドフィンチ バイオ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴールドフィンチ バイオ，インク． filed Critical ゴールドフィンチ バイオ，インク．
Publication of JP2022551580A publication Critical patent/JP2022551580A/ja
Publication of JP2022551580A5 publication Critical patent/JP2022551580A5/ja
Priority to JP2025150734A priority Critical patent/JP2025183335A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022520229A 2019-10-04 2020-10-05 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置 Pending JP2022551580A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025150734A JP2025183335A (ja) 2019-10-04 2025-09-11 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910758P 2019-10-04 2019-10-04
US62/910,758 2019-10-04
PCT/US2020/054282 WO2021067946A1 (en) 2019-10-04 2020-10-05 Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025150734A Division JP2025183335A (ja) 2019-10-04 2025-09-11 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置

Publications (2)

Publication Number Publication Date
JP2022551580A true JP2022551580A (ja) 2022-12-12
JP2022551580A5 JP2022551580A5 (https=) 2023-10-12

Family

ID=75337492

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520229A Pending JP2022551580A (ja) 2019-10-04 2020-10-05 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
JP2025150734A Pending JP2025183335A (ja) 2019-10-04 2025-09-11 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025150734A Pending JP2025183335A (ja) 2019-10-04 2025-09-11 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置

Country Status (10)

Country Link
US (1) US20240091303A1 (https=)
EP (1) EP4037680A4 (https=)
JP (2) JP2022551580A (https=)
KR (1) KR20220079907A (https=)
AU (1) AU2020357178A1 (https=)
CA (1) CA3156814A1 (https=)
IL (1) IL291903A (https=)
MX (1) MX2022004049A (https=)
PH (1) PH12022550818A1 (https=)
WO (1) WO2021067946A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71645A (fr) * 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
CN115927202A (zh) * 2023-01-10 2023-04-07 北京爱思益普生物科技股份有限公司 一种trpc5突变细胞株及其构建方法和应用
WO2024164818A1 (zh) * 2023-02-08 2024-08-15 中国科学院上海药物研究所 黄嘌呤类化合物及其用途
CN116919965B (zh) * 2023-05-24 2024-05-17 徐州医科大学 一种trpml1特异性小分子抑制剂ml-si3的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
JP5795311B2 (ja) * 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
US20110135574A1 (en) * 2009-11-16 2011-06-09 Anna Greka Methods of treating kidney disease
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
DK3652176T3 (da) * 2017-07-11 2022-01-17 Boehringer Ingelheim Int Substituerede xanthinderivater
WO2019028309A1 (en) * 2017-08-04 2019-02-07 Goldfinch Bio, Inc. AZAINDOLES AND THEIR METHODS OF USE
WO2019028308A1 (en) * 2017-08-04 2019-02-07 Goldfinch Bio, Inc. BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES AND METHODS OF USE
US11370769B2 (en) * 2017-09-07 2022-06-28 Board Of Regents Of The University Of Nebraska TRPC5 inhibitors and methods of using same
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
CA3093084A1 (en) * 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
MA71645A (fr) * 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
""NCT03970122, FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects"", CRINICAL TRIALS（インターネット）, JPN6025018858, 2 June 2020 (2020-06-02), ISSN: 0005593983 *
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 814, JPN6024035138, 2017, pages 187 - 195, ISSN: 0005593979 *
MOL. NUTR. FOOD RES., vol. Vol.63, 1900489, JPN6024035139, 15 September 2019 (2019-09-15), pages 1 - 13, ISSN: 0005593980 *
MUNDEL, P. ET AL.: "SUN-190 GFB-887, A SMALL MOLECULE INHIBITOR OF TRPC5, PROTECTS AGAINST PODOCYTE INJURY AND ATTENUATE", KIDNEY INTERNATIONAL REPORTS, vol. 4, JPN6025018855, July 2019 (2019-07-01), pages 237, ISSN: 0005593981 *
PLOS ONE, vol. Vol.13, No.1, e0191225, JPN6025018857, 2018, pages 1 - 32, ISSN: 0005593982 *
SCIENCE, vol. 358, JPN6024035136, 2017, pages 1332 - 1336, ISSN: 0005593977 *
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 12, JPN6024035137, 2013, pages 5298 - 5309, ISSN: 0005593978 *

Also Published As

Publication number Publication date
CA3156814A1 (en) 2021-04-08
KR20220079907A (ko) 2022-06-14
IL291903A (en) 2022-06-01
JP2025183335A (ja) 2025-12-16
MX2022004049A (es) 2022-07-11
PH12022550818A1 (en) 2023-09-11
EP4037680A4 (en) 2023-10-04
EP4037680A1 (en) 2022-08-10
WO2021067946A1 (en) 2021-04-08
AU2020357178A1 (en) 2022-05-12
US20240091303A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
JP2025183335A (ja) 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
AU2018369784B2 (en) RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
WO2009133141A2 (en) New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
US11382908B2 (en) Compositions and methods for treating inflammatory bowel disease
JP2022000482A (ja) Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法
WO2020206623A1 (en) Crystal forms
JP2018504416A (ja) チロシンキナーゼ阻害剤を用いる組成物および方法
US20250136545A1 (en) Novel sulfonamide derivatives having selective nox inhibiting activity
CA3168026A1 (en) Compositions and methods for treating age-related diseases and premature aging disorders
US20200377505A1 (en) Benzimidazoles and aza-benzimidazoles, and methods of use thereof
KR20180007307A (ko) 자가포식 향상물질 및 그 용도
SG175816A1 (en) Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
JPWO2004093910A1 (ja) ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
US20090202524A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
MD4802C1 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
US20250064892A1 (en) Use of soluble pro(renin) receptor to treat metabolic disorders and related conditions
KR20220041847A (ko) 섬유성 병리를 치료하기 위한 화합물 및 방법
US20250312332A1 (en) Treatment of muscle fibrosis
US20210115036A1 (en) Azaindoles and methods of use thereof
US20240150286A1 (en) PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARy) LIGANDS AND METHODS OF USE AS TREATMENTS FOR INSULIN RESISTANCE, OBESITY, FATTY LIVER DISEASE, AND TYPE 2 DIABETES
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
KR102844495B1 (ko) 티플락스티닌을 포함하는 복막 섬유증의 개선, 예방 또는 치료용 조성물
AU2020272030C1 (en) Crystal forms of a pyridazinone TRPC inhibitor
US20200270216A1 (en) Compositions and methods for inhibiting n-smase2
US20210030719A1 (en) Grp94 inhibitors to treat steroid-induced ocular hypertensions and glaucomas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250228

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250514